Devices Treat Obesity Patients without Options

Early intervention is the general rule for success in treating many diseases, but in obesity, patients have to be in bad shape before they're eligible for the most efficacious treatments, which are surgical interventions. Companies with minimally invasive--and anatomy sparing--devices hope to change that paradigm.

Whether one eats to live or lives to eat, modern man’s relationship with food has clearly gotten out of control. In the US, more than two-thirds of adults age 20 and older are now classified as overweight or obese, to the tune of 127 million overweight adults, 66 million obese adults ,and 9 million morbidly obese adults, according to a report published in February by the Medtech Insight division of Windhover Information. (See, "US Marketsfor Obesity Drugs and Bariatric Surgical Devices".) The US is by no means the only country in which the combination of an increasingly sedentary lifestyle and a diet high in fats has created an obesity epidemic. The prevalence of obesity is increasing across the globe, from Europe to Southeast Asia. Today, more than 1.1 billion adults worldwide are overweight and 312 million of them are obese. What bodes even worse for the future: 155 million children worldwide are overweight or obese according to the World Health Organization.

Health institutions have taken to calling obesity an epidemic, to make it clear that treating it is not an aesthetic issue. Obesity shortens the life spans of patients. Excess weight...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.